---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-225858"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:10:21.744836+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Perspective Therapeutics files routine corporate presentation update; no material new disclosure

## Summary
- Presentation shows [212Pb]VMT-α-NET Phase 1/2a data in NET with confirmed partial response in patient 103-105.
- Tolerability data: mild, transient creatinine increase; no unexpected safety signals.
- Pipeline includes [212Pb]VMT01 for melanoma and [212Pb]PSV359 targeting FAP-α in trials.
- Pre-targeting platform and supply chain manufacturing infrastructure also highlighted.

## SEC filing metadata
- accession: 0001193125-25-225858
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312525225858/0001193125-25-225858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312525225858/catx-20251001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-225858
- JSON: https://secwatch.observer/filing/0001193125-25-225858.json
- Plain text: https://secwatch.observer/filing/0001193125-25-225858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.